The VHRC Team

Who We Are. What We Do.

Joel Ehrenzweig, DVM, MRCVS
Founder & CEO

JE.Pic.jpg

Dr. Ehrenzweig received a B.S. in Biology from the City College of New York and a Doctor of Veterinary Medicine with Honors Standing from the Ontario Veterinary College.  During twenty-five years of multi-site clinical practice, Dr. Ehrenzweig owned five animal hospitals in New York City and three in Boston. He has held technical service, turn-around, marketing, and consulting positions for companies within both the human and animal health industries.

Dr. Ehrenzweig’s industry experience includes positions as Site Director for Covance, as well as business development roles at leading CROs, which offered global access to unique and comprehensive clinical research and furthered insights into how tomorrow’s science will benefit pets and their people. His entrepreneurial passion for biotech research continues to support pre-clinical human science that may also facilitate the translation of these cutting-edge developments into the animal health arena. 

Before coming to market, every new product intended for use for people must travel a pre-clinical route that tests its safety and efficacy for the purpose for which it is being developed. Many of the medical and surgical problems that physicians diagnose and treat are similar to conditions experienced by animals, including cancer, inflammatory disease, and age-related conditions.

 

Since validated large animal research models are often unavailable for these indications, VHRC taps into the skills and expertise of a global veterinary network to identify and enroll client-owned patients that can be used in clinical studies.  This first-to-market initiative expedites clinical trials for new products, medications, therapies, and devices for both humans and animals. VHRC accelerates life science innovations and facilitates meeting the regulatory requirements and practical marketing needs of companies.

The VHRC team’s relationships with general practices, specialists, and industry networks can reduce complexity, enhance efficiency, and accelerate the development of products for entrepreneurs and innovators worldwide, as well as large and small pharma and biotechs

 

Rob Hunter, PhD

Chief Science Officer

 

 

 

Rob Hunter, Ph.D., is an industry-leading Veterinary Pharmacologist who brings over twenty-eight years of veterinary and human drug development and FDA/USDA regulatory experience to VHRC.

 

Working with NASA, Pfizer AH, Elanco, Parnell, and Provetica, Dr. Hunter has contributed to the US and/or global approvals of Revolution®, Dectomax®, Aviax®, Doxidyl™, A180®, tylosin, Micotil®, Ovugel®, Kexxtone®, ractopamine, Experior, Posilac®, and Pulmotil®. 

 

An internationally recognized subject matter expert on pharmacokinetics, antimicrobial PK/PD, interspecies allometry, drug metabolism, tissue residues for human food safety with bioanalytical support, he has served on and chaired Animal Health Institute committees and has represented the U.S. veterinary pharmaceutical industry on the VICH BE expert committee and companies at conferences and at regulatory meetings with CVM/FDA, EMA/CVMP, APVMA, VDD (Canada), NVQRS/QIA (South Korea), Thailand FDA, NVAL (Japan), Ministry of Agriculture (Vietnam), and IVDC (China).

An adjunct professor at the University of Kansas and instructor at Kansas State University, he is President of the American Academy of Veterinary Pharmacology and Therapeutics; an Editorial Board member for the Journal of Veterinary Pharmacology & Therapeutics, Journal of Zoo & Wildlife Medicine, Research in Zoology, American Journal of Bioavailability & Bioequivalence, and the Journal of Primates.

 

Dr. Hunter completed his Ph.D. in Veterinary Pharmacology at Louisiana State University and his MS in Veterinary Physiology at Texas A&M University.

As VHRC's Chief Science Officer, Dr. Hunter focuses on

  • Veterinary drug approval & regulation

  • Antimicrobial agents including antibiotics, biosimilars Susceptibility testing, and pharmacodynamics

  • Veterinary pharmacology and pharmacokinetics

  • Veterinary bioequivalence

  • One Health and Translational Veterinary Medicine as a Service (TVMaaS) 

  • Pre-clinical and GLP studies in companion, food production, and minor species (MUMS)

  • Regulatory guidance for animals, human food safety, dossiers

  • Veterinary product development, market assessment, veterinary devices

  • Drug metabolism, animal safety

  • Residue withdrawal times, marker and total residue studies 

  • Regulatory and strategic consulting

123-456-7890

  • Facebook
  • Twitter
  • LinkedIn
RPH headshot coat full_edited_edited.jpg

Rob Hunter, PhD
Chief Science & Regulatory Officer

Rob Hunter, Ph.D., is an industry-leading Veterinary Pharmacologist who brings over twenty-eight years of veterinary and human drug development and FDA/USDA regulatory experience to VHRC.

Dr. Hunter completed his Ph.D. in Veterinary Pharmacology at Louisiana State University and received an MS in Veterinary Physiology at Texas A&M University. An internationally recognized subject matter expert on pharmacokinetics, antimicrobial PK/PD, interspecies allometry, drug metabolism, tissue residues for human food safety with bioanalytical support, he has served on and chaired Animal Health Institute committees and has represented the U.S. veterinary pharmaceutical industry on the VICH BE expert committee.

An adjunct professor at the University of Kansas and instructor at Kansas State University, he is President of the American Academy of Veterinary Pharmacology and Therapeutics; an Editorial Board member for the Journal of Veterinary Pharmacology & Therapeutics, Journal of Zoo & Wildlife Medicine, Research in Zoology, American Journal of Bioavailability & Bioequivalence, and the Journal of Primates.

 

Working with NASA, Pfizer AH, Elanco, Parnell, and Provetica, Dr. Hunter has contributed to the US and/or global approvals of Revolution®, Dectomax®, Aviax®, Doxidyl™, A180®, tylosin, Micotil®, Ovugel®, Kexxtone®, ractopamine, Experior, Posilac®, and Pulmotil®. Representing companies at conferences and at regulatory meetings with CVM/FDA, EMA/CVMP, APVMA, VDD (Canada), NVQRS/QIA (South Korea), Thailand FDA, NVAL (Japan), Ministry of Agriculture (Vietnam), and IVDC (China).

As VHRC's Chief Science & Regulatory Officer, Dr. Hunter focuses on

  • Veterinary drug approval & regulation

  • Antimicrobial agents including antibiotics, biosimilars Susceptibility testing, and pharmacodynamics

  • Veterinary pharmacology and pharmacokinetics

  • Veterinary bioequivalence

  • One Health and Translational Veterinary Medicine as a Service (TVMaaS) 

  • Pre-clinical and GLP studies in companion, food production, and minor species (MUMS)

  • Regulatory guidance for animals, human food safety, dossiers

  • Veterinary product development, market assessment, veterinary devices

  • Drug metabolism, animal safety

  • Residue withdrawal times, marker and total residue studies 

  • Regulatory and strategic consulting

 

Jules d’Assonville, DVM, M.Med.Vet.

                                                         Partner and Co-Founder

                                                          Chief Operation Officer Asia Pacific

 

 

 

 

 

Dr. d'Assonville holds bachelor’s degrees in agricultural sciences and  veterinary sciences. He has over 20 years of commercial experience as proprietor of a business development consultancy for veterinary pharmaceutical, animal health companies and Biotech enterprises.  

He previously owned three veterinary clinics and as a serial entrepreneur co-founded several business startups. He is currently principal of a consultancy, acting  Managing Director of Pacific AgVet and on the Board of a number of  companies. 

He resides in Australia after relocating from South Africa to the USA for several years with current business interests in South Africa, USA and Australia.  His extensive global experience in agriculture, veterinary research, product development, animal health and pharmaceutical business environments supported successes of several entrepreneurial projects and enterprises.  

Kim Agnew, BSc, BVSc, MACVSc
Chief Science & Regulatory Officer Asia Pacific

Dr. Agnew, BSc (Hons), BVSc, MACVSc, brings  25 years of experience in the animal health industry to VHRS-APAC. Expertise in business and product development, regulatory affairs, clinical research, technical support and pharmacovigilance, are founded on 10 years in mixed animal veterinary practice in New Zealand, focused on dairy and swine industries. Dr. Agnew's roles since entering the animal health industry in 1995, include have involved management of research and regulatory affairs, regional regulatory management, and the leadership of a global R&D research hub.

 

Dr. Agnew worked for 20 years at Elanco Animal Health in a variety of management roles including Research and Regulatory Manager, Innovation Manager and Associate Director of Research and Development. Following this, he worked for 5 years at Merial, now Boehringer Ingelheim, as the Research and Development Leader of a specialized group executing the development of incremental innovation for ruminant markets in Australia and New Zealand. Capabilities of this group ranged from ground-up formulation development to proposed product market assessments, clinical study designs and execution, and preparation of required regulatory dossiers for submission.  

 

Dr. Agnew has extensive expertise working and collaborating with the Agricultural Compounds and Veterinary Medicines (ACVM) Agency and the Environmental and Risk Management Agency (ERMA), now the Environmental Protection Authority (EPA), in New Zealand, as well as the Australian Pesticides and Veterinary Medicines Authority (APVMA). He has served on key regulatory industry bodies linked to Animal Medicines Australia, and is a former President of the Australian Vets in Industry Special Interest Group (SIG) of the Australian Veterinary Association (AVA). He has also collaborated with industry and government groups during stakeholder discussions regarding the potential introduction of contentious technologies to the Australian and New Zealand markets.

 

Regulatory experience includes submission and negotiation for a variety of successful approvals including Rumensin drenchable liquid and trough treatment for dairy cattle; Extinosad suspension concentrate and pour-on for sheep; Cyrex for sheep; Comfortis (spinosad) for dogs; Pulmotil (tilmocosin) for swine; Demize for cattle; and Micotil for cattle.

 

Dr. Agnew's a passion for the development and commercialization of new products has been directed at improving animal health, welfare, and farmer productivity. He has developed a strong understanding of the business development and market research processes required for the successful technology commercialization, including the development and management of research plans and studies required to successfully meet local and global regulatory requirements. As both a team lead and contributor, Dr. Agnew has been involved in the ground-up development and commercialization of 15 new products, numerous line extensions to existing products, and is named in 6 product development patents.

 

Dr. Agnew's broad expert contact network has been instrumental in gaining industry support for multiple Australian Research Council (ARC) Linkage Grant collaborations and research projects leveraging the very high quality of science research available in Australia and New Zealand. Active projects remain confidential.

Contact Us